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PURPOSE: The present study was designed to determine the normal range of serum beta 2-microglobulin (Sb2M)
levels among healthy volunteers in Brazil. Levels of Sb2M are elevated in human immunodeficiency virus (HIV)-infected
patients and have been shown to be the best predictor of HIV infection status and of some malignant disorders, especially
multiple myeloma. In order to achieve its optimal use in Brazilian clinical diagnosis, an adequate reference interval study
was performed for Sb2M IMMULITE® assay, based on the fact that its reference range limits were evaluated among European
populations.
METHODS: Ninety-six healthy blood donors were evaluated, and Sb2M levels were measured by chemiluminescent
enzyme immunoassay using the IMMULITE® automated analyzer.
RESULTS: A normal range of Sb2M values, established by a nonparametric statistical method, was 1.05 to 3.9 mg/mL,
with the upper limit being higher than that reported elsewhere.
CONCLUSIONS: This study presented new data indicating that there is a significant difference between the current
reference limits for Sb2M IMMULITE® assay and those found in Brazil, providing evidence that significant differences in
range of normal values may occur among different populations, and that these new values should be considered for Brazilian
individuals.
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Prognostic value.
Beta 2-microglobulin (b2M) a protein found in all nu-
cleated cells, is associated with histocompatibility class 1
antigens on cell surface membranes (particularly abundant
on lymphocytes and monocytes).1 It was first discovered in
the urine of patients with renal failure.2 Because of its low
molecular weight (11,800 daltons), 95% of all free b2M in
plasma is eliminated by glomerular filtration, and 99.9%
of it taken up by proximal tubular cells. In the presence of
a normal renal filtration rate, elevated serum b2M (Sb2M)
levels indicate high b2M production or release3. Upon ac-
tivation of the immune system, both B- and T-lymphocytes
actively release b2M into circulation from where it is later
eliminated via glomerular filtration and tubular reabsorp-
tion.4 Increased Sb2M concentrations have been found in
patients with blood cells dyscrasias, including multiple
myeloma,5,6 malignant lymphoproliferative disorders,7 my-
eloproliferative disorders,8 certain viral infections such as
HIV infection9, cytomegalovirus, non-A and non-B hepati-
tis, and infectious mononucleosis.10 The level of Sb2M is
also used as an important prognostic factor in patients with
multiple myeloma5,6 and HIV infections.9
The normal reference range for Sb2M in healthy individu-
als found in the literature was determined using North Ameri-
can and European populations (DPC Immulite® assay). In an
attempt to determine the normal range of Sb2M levels among
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asymptomatic seronegative African individuals, Piwowar et
al. (1995)10 found that 50% of these subjects had abnormal
values (mean values 2.35 mg/mL). In another study, the mean
Sb2M value among healthy volunteers was 1.36 mg/mL.11
In this report, we describe Sb2M values in healthy Brazilian
subjects from a group of blood donors at the Hematology
and Hemotherapy Center of Santa Catarina (HEMOSC).
SUBJECTS
Blood donors, men and nonpregnant women ranging
from 25 to 50 years of age, were included in the study. All
individuals underwent a clinical assessment evaluated by
HEMOSC, including questionnaires and screening labora-
tory tests according to Brazilian legal criteria. All volun-
teers fulfilling these criteria gave verbal and written con-
sent to have an additional 5 mL of blood drawn for the study
purpose. The experimental protocol was approved by the
Ethical Committee of the University Hospital of
Florianópolis, Federal University of Santa Catarina.
METHODS
Whole blood was collected with a Vacutainer system in
10-mL dry tubes, and serum was separated by centrifuga-
tion. In order to eliminate lipid components, serum sam-
ples were ultracentrifuged at 18000 g for 20 min. All blood
samples were obtained between 2:00 p.m. and 6:00 p.m. and
were processed within 5 h after venipuncture. Samples were
prediluted 1-in-41 in b2M Sample Diluent (IMMULITE®
Beta–2 Microglobulin kit, DPC, USA) according to the
manufacturer’s instructions, and 5 mL were required for the
assay procedure. Sb2M was measured by a solid-phase 2-
site chemiluminescent enzyme immunoassay using the
IMMULITE® Automated Analyzer (DPC, Los Angeles, USA).
Statistical analysis
In the reference range study for the DPC IMMULITE®
assay, the mean value was 1.26 mg/mL. The National Com-
mittee for Clinical Laboratory Standards (NCCLS) addresses
the use of a priori and a posteriori exclusion criteria to ob-
tain a healthy samples.12 Therefore, all subjects with Sb2M
values greater than 2.0 mg/mL were clinically reevaluated
for value acceptance to ensure that every individual was
“healthy”. Data were entered and analyzed with Microsoft
Excel software. The mean and standard deviation values
were calculated. The 95th-percentile reference ranges were
determined by using 2.5 and 97.5 percentiles. According
to the procedure recommended by the NCCLS, the obser-
vations were ranked according to size, and the 2.5 and 97.5
percentiles were obtained as the 0.025 (n + 1) and 0.975 (n
+ 1) ordered observations respectively (n= sample size). If
the estimated rank values were not integers, linear interpo-
lation was carried out.12
RESULTS
Ninety-six Brazilian blood donors, 60 men and 36
women, with mean age (yr) of 33, were included in the
study. Values of Sb2M ranged between 1.05 and 3.9 mg/
mL, as shown in Figure 1, and the mean was 2.46 mg/mL
(standard deviation [SD] = 0.73). Therefore, using 97.5th
percentile according to a routine nonparametric method,12
3.9 mg/mL was considered the upper normal limit. The
range established was 1.3–3.9 mg/mL.
Figure 1 - Serum beta 2-microglobulin (Sb2M) levels in blood donors (mg/mL) plotted versus its frequency distribution in percentage.
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DISCUSSION
Researchers worldwide have reported the usefulness of
Sb2M as a reliable maker in evaluating progression of HIV-
infection and multiple myeloma.5-8,10,13 In HIV-infected sub-
jects, Sb2M appears to be a better predictor of HIV infec-
tion status than CD4 counts and also a better predictor of
survival, with increased Sb2M levels being associated with
disease progression.10
Increased production and consequent release of Sb2M
into body fluids have been reported in patients with multi-
ple myeloma. The importance of these data for clinicians
is based on the fact that myeloma plasma cells produce
Sb2M. Therefore, it is assumed that Sb2M values could in-
dicate not only the size but also the proliferative activity
of the myeloma cells13 and could be accepted as a nonspe-
cific maker of tumor mass.5,6,13,14 In addition, the prognos-
tic role of Sb2M in other proliferative disorders has been
confirmed by many authors,7,14,15 facilitating clinical assess-
ment.15 On the other hand, it has been reported that in pa-
tients with low glomerular filtration rate, Sb2M levels were
raised and laboratory findings should be interpreted with
caution.6,7,13
Reference intervals are used clinically, together with
additional information, as guidelines concerning the state
of the patient. The reference range study for IMMULITE®
Sb2M (1.0–1.7 mg/mL, mean 1.26 mg/mL) defined by the
manufacturer was determined using serum samples from al-
most 800 adult volunteers, including both men and non-
pregnant women, ranging from 20 to 70 years of age. The
subjects were selected based on questionnaires. Samples
were collected in France, Germany, the Netherlands, and
Portugal, and values obtained were analyzed
nonparametrically. The suggested upper limit was 1.7 mg/
mL. These values may not be representative for Brazilian
individuals. In the absence of adequate reference range lim-
its for Sb2M derived from any Brazilian population, many
investigators have been using data obtained from North
American and European subjects that presented upper lim-
its 2.3 times lower than that obtained in the present study.
The NCCLS recommends that nonparametric reference
intervals be used and that the sample size, n, should con-
sist of at least 120 values in order to compute a 95% refer-
ence interval, 2.5% and 97.5% points of the distribution12.
This number is the minimum number of values needed for
construction of the confidence intervals giving information
about the accuracy of the calculated reference limits.
In this study, 96 samples were evaluated. Our goal was
not to produce new reference intervals, but to bring more
focus on the need for every laboratory to produce its own
reference intervals for all parameters in spite of many diffi-
culties, including practical ones and high expenses.
The present study indicates that significantly different
ranges of Sb2M values may occur among different
populations, suggesting that each Brazilian laboratory
should establish its own reference limits.
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RESUMO
FILIPPIN FB e col. Valores de β2-Microglobulina em
Brasileiros saudáveis usando o sistema automatizado
DPC IMMULITE®. CLINICS 60(1):47-50, 2005.
OBJETIVO: O objetivo do presente estudo foi
determinar valores de referência de β2-Microglobulina sérica
(Sb2M) em voluntários saudáveis. Sabe-se que tal parâmetro
apresenta-se elevado em pacientes infectados com o vírus
da imunodeficiência humana (HIV) e tem se mostrado
melhor marcador da infecção por HIV e de desordens
malignas, especialmente mieloma múltiplo. De forma a se
obter o melhor diagnóstico clínico, um intervalo de
referência adequado de Sb2M para a população brasileira
foi determinado empregando-se o ensaio IMMULITE®; já
que este tem como parâmetro uma faixa de referência
determinada a partir de populações européias.
MÉTODOS: Noventa e seis doadores de sangue
saudáveis foram avaliados e os valores de Sb2M foram
medidos por método enzima imunoensaio
quimiluminescente usando analisador automatizado
IMMULITE®.
RESULTADOS: Os valores de Sb2M, estabelecidos por
método estatístico não paramétrico, apresentaram-se entre
1.05 e 3.9 mg/ml, sendo que o limite superior obtido foi
maior que o relatado em outros trabalhos.
CONCLUSÃO: Este estudo apresentou novos valores,
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indicando que existe uma diferença significante entre os
limites de referência de Sb2M disponibilizados para o
IMMULITE® e os encontrados no presente trabalho,
evidenciando a ocorrência de variações importantes entre
diferentes populações e que novos valores devem ser
considerados para brasileiros.
UNITERMOS: β2–microglobulina. Intervalo de
referência. Imunoensaio quimiluminescente. Voluntários
saudáveis. Valor prognóstico.
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